Journal article
Relaxin and castration in male mice protect from, but testosterone exacerbates, age-related cardiac and renal fibrosis, whereas estrogens are an independent determinant of organ size
TD Hewitson, C Zhao, B Wigg, SW Lee, ER Simpson, WC Boon, CS Samuel
Endocrinology | ENDOCRINE SOC | Published : 2012
DOI: 10.1210/en.2011-1311
Abstract
This study determined the effects of castration and hormone replacement therapy on the age-related cardiac and renal pathology of male relaxin gene-knockout (RlnKO) and age-matched wild-type (RlnWT) mice and that of aged male aromatase knockout (ArKO) mice, which lack estrogens and have 5-10 times the androgen levels of male wild-type mice. One-month-old RlnWT and RlnKO mice were bilaterally gonadectomized or sham operated and maintained until 12 months. Subgroups of castrated animals received testosterone or 17 β-estradiol treatment from 9 to 12 months. Male ArKO mice and aromatase wild-type mice were aged to 12 months. Collected heart and kidney tissues were assessed for changes in organ s..
View full abstractGrants
Awarded by NHMRC
Funding Acknowledgements
This work was supported by a National Heart Foundation of Australia/National Health and Medical Research Council of Australia (NHMRC) R. D. Wright Fellowship (to C. S. S.), an NHMRC Senior Principal Research Fellowship (to E. R. S.), an NHMRC Project Grant (494813) (to W. C. B.), and by the Victorian Government's Operational Infrastructure Support Program.